Telix Pharmaceuticals

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, that specializes in the field of theranostics. By integrating molecular imaging with targeted radiation, the company provides a comprehensive approach to cancer care, focusing on urologic, neurologic, and musculoskeletal oncology. Telix has successfully transitioned from a clinical-stage startup to a vertically integrated powerhouse, managing an end-to-end infrastructure that spans drug development, manufacturing, and global distribution. The company's business model is built around the theranostic cycle, which uses diagnostic imaging to inform and guide therapeutic interventions. With key products like the FDA-approved Illuccix and a robust pipeline of diagnostic and therapeutic candidates, Telix is at the forefront of precision medicine. Through strategic acquisitions and the development of proprietary surgical and AI-driven diagnostic tools, the company continues to expand its footprint across Australia, the United States, Europe, and Japan.

To deliver on the promise of precision medicine through targeted radiation, helping people with cancer and rare diseases live longer, better-quality lives.

• FDA approval of Illuccix in 2021
• Dual-listing on the ASX and NASDAQ
• Vertical integration through strategic acquisitions of Lightpoint Medical, ARTMS, and RLS Radiopharmacies
• Development of the SENSEI miniature gamma probe for robotic-assisted surgery

Sources

• Telix Pharmaceuticals Official Website
• ASX Company Profile